A subset analysis of diabetic patients in the SPIRIT II Clinical trial of the XIENCE V Everolimus Eluting Stent System showed nearly identical rates of in-stent late loss at six months in diabetic patients as those observed in the overall study patient population, according to new results presented at TCT last week.
Abbott also presented new positive nine-month safety data from the SPIRIT II trial, which showed no additional occurrences of MACE (Major Adverse Cardiac Event) or stent thrombosis between six and nine months.
Late loss is a measure of the change in the vessel diameter between the time immediately following stent placement and at six months.
XIENCE V has received a CE mark in Europe and is currently an investigational device in the United States and Japan.
July 02, 2024 
